查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
血友病市場規模、佔有率和趨勢分析報告：按類型、治療類型、治療方法、配銷通路、地區、細分市場趨勢，2023-2030 年
市場調查報告書
商品編碼
1321338

血友病市場規模、佔有率和趨勢分析報告：按類型、治療類型、治療方法、配銷通路、地區、細分市場趨勢，2023-2030 年

Hemophilia Market Size, Share & Trends Analysis Report By Type (Hemophilia A), By Treatment Type (On-demand), By Therapy (Gene Therapy & Monoclonal Antibodies), By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 105 Pages | 商品交期: 2-10個工作天內

價格

血友病市場成長和趨勢

Grand View Research, Inc.最新報告顯示，預計2030年全球血友病市場規模將達到210.7億美元，2023年至2030年年複合成長率為6.6%。

用於治療血友病的基因療法和單克隆抗體的批准以及多種此類候選藥物的出現是市場成長的關鍵促進因素。此外，由於死亡率降低而延長血友病患者的預期壽命也是推動市場成長的關鍵因素。

控制血友病新療法的開拓和推出正在推動市場成長。例如，2020年4月，FDA批准了基因工程產品Sevenfact【凝血因子VIIa（基因重組）-jncw】作為控制青少年（12歲及以上）和成人出血發作的治療選擇。此外，BioMarin 的 A 型血友病治療藥物 Roctavian 僅在歐洲獲得批准，而 CSL 的 Hemgenix (etranacogene dezaparvovec-drib) 在美國和歐洲均獲得批准。 Biomarin 的 Roctavian 在之前被拒絕後正在美國FDA 接受審查，PDUFA 日期定為 2023 年 6 月 30 日。

領先公司通過專注於新產品開發和戰略聯盟來擴大其地域影響力。例如，2022 年 4 月，諾和諾德 (Novo Nordisk) A/S 與加拿大血液服務公司 (Canadian Blood Services) 合作，加強其 Esperoct 和 Zonovate 的產品組合，這些產品作為 A 型治療藥物進行銷售。此外，2023 年 2 月，賽諾菲的 Artuvio 獲得 FDA 批准，這是一種治療 A 型血友病的 VIII 因子替代療法。

然而，在中國和印度等新興國家，輕至中度症狀的診斷延遲是一個主要障礙。市場面臨的另一個主要挑戰是，由於高成本和缺乏長期資料，獲得基因治療可能會出現問題。例如，Hemgenics 治療（2022 年批准）每次治療費用為 350 萬美元，是世界上最昂貴的治療方法。

血友病市場報告亮點

  • 在血友病市場中，由於A型血友病的高患病率以及多種治療藥物的存在，A型血友病佔據最大佔有率。預計基因治療的批准也將在預測期內實現最高的年複合成長率。
  • 從銷售管道來看，2022年專科藥品領域佔據最大市場佔有率。
  • 從治療方式來看，因子替代療法在2022年佔據血友病市場的最大佔有率。這是因為它是一種既用於預防又用於按需治療的主要治療方法。
  • 北美是 2022 年血友病市場創收最高的地區，這要歸功於關鍵參與者的存在、法規支持、患者意識和有利的財務支持。

目錄

第1章 調查方法

第2章 市場定義

第3章 執行摘要

第4章 血友病市場變量、趨勢和範圍

  • 血友病市場預測
    • 母公司市場預測
  • 繪製採用和成長預測
  • 市場促進因素分析
    • 新生兒數量增加
    • 有利的政府舉措
    • 加大研發力度和新產品開發
    • 更多地採用預防性治療
  • 市場抑制因素分析
    • 採購治療藥物的成本高昂
  • 波特五力分析
  • PESTLE分析
  • 管道分析

第5章 血友病市場 - 按類型細分分析，2018-2030

  • 全球血友病市場：類型變異分析
  • 甲型血友病
  • 乙型血友病
  • 其他

第6章 血友病市場 – 細分分析，按治療類型，2018-2030

  • 全球血友病市場：治療類型變異分析
  • 預防
  • 一經請求
  • 康復

第7章 血友病市場 - 細分分析（按治療方法），2018-2030 年

  • 全球血友病市場：治療波動分析
  • 因子替代療法
  • 基因治療和單克隆抗體
  • 去氨加壓素和纖維蛋白密封劑

第8章 血友病市場 - 按銷售管道細分分析，2018-2030

  • 全球血友病市場：配銷通路變化分析
  • 醫院藥房
  • 專業藥房

第9章 血友病市場 - 區域細分分析，2018-2030

  • 血友病市場：區域展望
  • 北美
    • 北美血友病市場估計和預測，2018-2030
    • 美國
    • 加拿大
  • 歐洲
    • 2018-2030 年歐洲血友病市場估計和預測
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 2018-2030 年亞太地區血友病市場估計和預測
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 韓國
    • 鯛魚
  • 拉丁美洲
    • 拉丁美洲血友病市場估計和預測，2018-2030 年
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東和非洲
    • 中東和非洲血友病市場估計和預測，2018-2030 年
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第10章 競爭形勢

  • 企業分類
  • 參與企業概覽
  • 財務績效
  • 產品基準
  • 公司市場地位
  • 2022 年公司市場佔有率分析
  • 企業熱圖分析
  • 戰略舉措
  • 公司簡介
    • NOVO NORDISK A/S
    • TAKEDA PHARMACEUTICAL COMPANY LIMITED
    • F. HOFFMANN LA-ROCHE LTD.
    • BAYER AG
    • PFIZER, INC.
    • CSL BEHRING
    • BIOMARIN
    • OCTOPHARMA AG
    • SANOFI
    • SPARK THERAPEUTICS, INC.
Product Code: 978-1-68038-989-0

Hemophilia Market Growth & Trends

The global hemophilia market size is expected to reach USD 21.07 billion by 2030, expanding at a CAGR of 6.6% from 2023 to 2030, according to a new report by Grand View Research, Inc. The approval of gene therapy and monoclonal antibodies for treating hemophilia and the presence of multiple such candidates in the pipeline are major drivers for market growth. In addition, the increasing life expectancy of hemophilia patients due to reduced mortality is another key factor driving market growth.

The development and launch of novel therapies to control hemophilia are propelling the market growth. For instance, in April 2020, FDA approved the genetically engineered product Sevenfact [coagulation factor VIIa (recombinant)-jncw] as a treatment option to control bleeding episodes in adolescents (of age group 12 years and above) and adults. Furthermore, the presence of 2 gene therapy products, BioMarin's Roctavian for hemophilia A, was approved only in Europe, and CSL's Hemgenix (etranacogene dezaparvovec-drib) was approved both in the U.S., and Europe demonstrates an opportunity for expansion in other regions. BioMarin's Roctavian is under review with the U.S. FDA after its previous rejection and has a PDUFA date set for June 30, 2023.

Major players are focused on developing new products and entering into strategic collaborations for enhanced geographic presence. For instance, in April 2022, Novo Nordisk A/S partnered with Canadian Blood Services to enhance its product offering with marketed drugs Esperoct and Zonovate, publicly available for treating type A. Moreover, in February 2023, Sanofi received FDA approval for its drug Altuviiio, a factor VIII replacement therapy for treating hemophilia A.

However, a key restraining factor is the delayed diagnosis of mild to moderate disease in developing countries such as China and India. Another key challenge for the market is the possible access issues for gene therapy due to its high cost and lack of long-term data. For instance, the cost of treatment using Hemgenix (Approved in 2022) is USD 3.5 million per treatment, making it the most expensive treatment in the world.

Hemophilia Market Report Highlights

  • The type A segment held the largest share of the hemophilia market owing to the higher prevalence of hemophilia A and the availability of multiple products for its treatment. This segment is also expected to grow at the highest CAGR during the forecast period owing to the approval of gene therapy
  • Based on the distribution channel, the specialty pharmacies segment held the largest market share in 2022, attributable to the specialized nature of the treatment required for the condition
  • By therapy factor replacement therapy held the largest share of the hemophilia market in 2022, as it is the major form of treatment used in both prophylaxis and on-demand treatment
  • North America was the largest revenue-generating region in the hemophilia market in 2022, which can be attributed to the presence of key players, regulatory support, patient awareness, and favorable funding assistance

Table of Contents

Chapter 1 Research Methodology

  • 1.1 Market Segmentation & Scope
    • 1.1.1 Estimates And Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database
    • 1.3.2 Gvr's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research
    • 1.3.5 Details Of Primary Research
  • 1.4 Information Or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis
      • 1.6.1.1 Approach 1: Commodity Flow Approach
      • 1.6.1.2 Approach 2: Country-Wise Market Estimation Using Bottom-Up Approach
  • 1.7 Global Market: Cagr Calculation
  • 1.8 Research Assumptions
  • 1.9 List Of Secondary Sources
  • 1.10 List Of Primary Sources
  • 1.11 Objectives
    • 1.11.1 Objective 1:
    • 1.11.2 Objective 2:
  • 1.12 List Of Abbreviations

Chapter 2 Market Definitions

Chapter 3 Executive Summary

  • 3.1 Market Summary

Chapter 4 Hemophilia Market Variables, Trends, & Scope

  • 4.1 Hemophilia Market Lineage Outlook
    • 4.1.1 Parent Market Outlook
  • 4.2 Penetration And Growth Prospect Mapping
  • 4.3 Market Driver Analysis
    • 4.3.1 Increasing Population Of Newborns
    • 4.3.2 Favorable Government Initiatives
    • 4.3.3 Rising R&D And New Product Development
    • 4.3.4 Rising Adoption Of Prophylaxis Treatment
  • 4.4 Market Restraint Analysis
    • 4.4.1 High Cost Associated With Procuring Treatment
  • 4.5 Porter's Five Forces Analysis
  • 4.6 Pestle Analysis
  • 4.7 Pipeline Analysis

Chapter 5 Hemophilia Market - Segment Analysis, By Type, 2018 - 2030 (USD Million)

  • 5.1 Global Hemophilia Market: Type Movement Analysis
  • 5.2. Hemophilia A5.2.1. Hemophilia A Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.3. Hemophilia B
    • 5.3.1. Hemophilia B Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Others
    • 5.4.1 Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 6 Hemophilia Market- Segment Analysis, By Treatment Type, 2018 - 2030 (USD Million)

  • 6.1 Global Hemophilia Market: Treatment Type Movement Analysis
  • 6.2. Prophylaxis
    • 6.2.1. Prophylaxis Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.3. On-Demand
    • 6.3.1. On-Demand Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Cure
    • 6.4.1. Cure Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 7 Hemophilia Market - Segment Analysis, By Therapy, 2018 - 2030 (USD Million)

  • 7.1 Global Hemophilia Market: Therapy Movement Analysis
  • 7.2. Factor Replacement Therapy
    • 7.2.1. Factor Replacement Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 7.2.1.1 Plasma Derived Factor Concentrates
      • 7.2.1.1.1 Plasma Derived Factor Concentrates Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 7.2.1.1.2 Factor Viii Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 7.2.1.1.3 Factor Ix Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 7.2.1.2 Recombinant Factor Concentrates
      • 7.2.1.2.1 Recombinant Factor Concentrates Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 7.2.1.2.2 Factor Viii Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 7.2.1.2.3 Factor Vii Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 7.2.1.2.4 Factor Vii Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Gene Therapy & Monoclonal Antibodies
    • 7.3.1. Gene Therapy & Monoclonal Antibodies Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Desmopressin & Fibrin Sealants
    • 7.4.1 Desmopressin & Fibrin Sealants Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 8 Hemophilia Market - Segment Analysis, By Distribution Channel, 2018 - 2030 (USD Million)

  • 8.1 Global Hemophilia Market: Distribution Channel Movement Analysis
  • 8.2. Hospital Pharmacies
    • 8.2.1. Hospital Pharmacies Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.3. Specialty Pharmacies
    • 8.3.1. Specialty Pharmacies Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 9 Hemophilia Market: - Segment Analysis, by Region, 2018 - 2030 (USD Million)

  • 9.1 Hemophilia Market: Regional Outlook
  • 9.2 North America
    • 9.2.1 North America Hemophilia Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.2.2 U.S.
      • 9.2.2.1 Key Country Dynamics
      • 9.2.2.2 U.S. Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
      • 9.2.2.3 Target Disease Prevalence
      • 9.2.2.4 Competitive Scenario
      • 9.2.2.5 Regulatory Framework
      • 9.2.2.6 Reimbursement Scenario
    • 9.2.3 Canada
      • 9.2.3.1 Key Country Dynamics
      • 9.2.3.2 Canada Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
      • 9.2.3.3 Target Disease Prevalence
      • 9.2.3.4 Competitive Scenario
      • 9.2.3.5 Regulatory Framework
      • 9.2.3.6 Reimbursement Scenario
  • 9.3 Europe
    • 9.3.1 Europe Hemophilia Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.3.2 UK
      • 9.3.2.1 Key Country Dynamics
      • 9.3.2.2 UK Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
      • 9.3.2.3 Target Disease Prevalence
      • 9.3.2.4 Competitive Scenario
      • 9.3.2.5 Regulatory Framework
      • 9.3.2.6 Reimbursement Scenario
    • 9.3.3 Germany
      • 9.3.3.1 Key Country Dynamics
      • 9.3.3.2 Germany Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
      • 9.3.3.3 Target Disease Prevalence
      • 9.3.3.4 Competitive Scenario
      • 9.3.3.5 Regulatory Framework
      • 9.3.3.6 Reimbursement Scenario
    • 9.3.4 France
      • 9.3.4.1 Key Country Dynamics
      • 9.3.4.2 France Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
      • 9.3.4.3 Target Disease Prevalence
      • 9.3.4.4 Competitive Scenario
      • 9.3.4.5 Regulatory Framework
      • 9.3.4.6 Reimbursement Scenario
    • 9.3.5 Italy
      • 9.3.5.1 Key Country Dynamics
      • 9.3.5.2 Italy Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
      • 9.3.5.3 Target Disease Prevalence
      • 9.3.5.4 Competitive Scenario
      • 9.3.5.5 Regulatory Framework
      • 9.3.5.6 Reimbursement Scenario
    • 9.3.6 Spain
      • 9.3.6.1 Key Country Dynamics
      • 9.3.6.2 Spain Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
      • 9.3.6.3 Target Disease Prevalence
      • 9.3.6.4 Competitive Scenario
      • 9.3.6.5 Regulatory Framework
      • 9.3.6.6 Reimbursement Scenario
    • 9.3.7 Denmark
      • 9.3.7.1 Key Country Dynamics
      • 9.3.7.2 Denmark Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
      • 9.3.7.3 Target Disease Prevalence
      • 9.3.7.4 Competitive Scenario
      • 9.3.7.5 Regulatory Framework
      • 9.3.7.6 Reimbursement Scenario
    • 9.3.8 Sweden
      • 9.3.8.1 Key Country Dynamics
      • 9.3.8.2 Sweden Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
      • 9.3.8.3 Target Disease Prevalence
      • 9.3.8.4 Competitive Scenario
      • 9.3.8.5 Regulatory Framework
      • 9.3.8.6 Reimbursement Scenario
    • 9.3.9 Norway
      • 9.3.9.1 Key Country Dynamics
      • 9.3.9.2 Norway Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
      • 9.3.9.3 Target Disease Prevalence
      • 9.3.9.4 Competitive Scenario
      • 9.3.9.5 Regulatory Framework
      • 9.3.9.6 Reimbursement Scenario
  • 9.4 Asia Pacific
    • 9.4.1 Asia Pacific Hemophilia Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.4.2 Japan
      • 9.4.2.1 Key Country Dynamics
      • 9.4.2.2 Japan Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
      • 9.4.2.3 Target Disease Prevalence
      • 9.4.2.4 Competitive Scenario
      • 9.4.2.5 Regulatory Framework
      • 9.4.2.6 Reimbursement Scenario
    • 9.4.3 China
      • 9.4.3.1 Key Country Dynamics
      • 9.4.3.2 China Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
      • 9.4.3.3 Target Disease Prevalence
      • 9.4.3.4 Competitive Scenario
      • 9.4.3.5 Regulatory Framework
      • 9.4.3.6 Reimbursement Scenario
    • 9.4.4 India
      • 9.4.4.1 Key Country Dynamics
      • 9.4.4.2 India Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
      • 9.4.4.3 Target Disease Prevalence
      • 9.4.4.4 Competitive Scenario
      • 9.4.4.5 Regulatory Framework
      • 9.4.4.6 Reimbursement Scenario
    • 9.4.5 Australia
      • 9.4.5.1 Key Country Dynamics
      • 9.4.5.2 Australia Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
      • 9.4.5.3 Target Disease Prevalence
      • 9.4.5.4 Competitive Scenario
      • 9.4.5.5 Regulatory Framework
      • 9.4.5.6 Reimbursement Scenario
    • 9.4.6 South Korea
      • 9.4.6.1 Key Country Dynamics
      • 9.4.6.2 South Korea Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
      • 9.4.6.3 Target Disease Prevalence
      • 9.4.6.4 Competitive Scenario
      • 9.4.6.5 Regulatory Framework
      • 9.4.6.6 Reimbursement Scenario
    • 9.4.7 Thailand
      • 9.4.7.1 Key Country Dynamics
      • 9.4.7.2 Thailand Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
      • 9.4.7.3 Target Disease Prevalence
      • 9.4.7.4 Competitive Scenario
      • 9.4.7.5 Regulatory Framework
      • 9.4.7.6 Reimbursement Scenario
  • 9.5 Latin America
    • 9.5.1 Latin America Hemophilia Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.5.2 Brazil
      • 9.5.2.1 Key Country Dynamics
      • 9.5.2.2 Brazil Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
      • 9.5.2.3 Target Disease Prevalence
      • 9.5.2.4 Competitive Scenario
      • 9.5.2.5 Regulatory Framework
      • 9.5.2.6 Reimbursement Scenario
    • 9.5.3 Mexico
      • 9.5.3.1 Key Country Dynamics
      • 9.5.3.2 Mexico Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
      • 9.5.3.3 Target Disease Prevalence
      • 9.5.3.4 Competitive Scenario
      • 9.5.3.5 Regulatory Framework
      • 9.5.3.6 Reimbursement Scenario
    • 9.5.4 Argentina
      • 9.5.4.1 Key Country Dynamics
      • 9.5.4.2 Argentina Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
      • 9.5.4.3 Target Disease Prevalence
      • 9.5.4.4 Competitive Scenario
      • 9.5.4.5 Regulatory Framework
      • 9.5.4.6 Reimbursement Scenario
  • 9.6 Middle East and Africa
    • 9.6.1 Middle East and Africa Hemophilia Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.6.1.1 Target Disease Prevalence
      • 9.6.1.2 Competitive Scenario
      • 9.6.1.3 Regulatory Framework
      • 9.6.1.4 Reimbursement Scenario
    • 9.6.2 South Africa
      • 9.6.2.1 Key Country Dynamics
      • 9.6.2.2 South Africa Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
      • 9.6.2.3 Target Disease Prevalence
      • 9.6.2.4 Competitive Scenario
      • 9.6.2.5 Regulatory Framework
      • 9.6.2.6 Reimbursement Scenario
    • 9.6.3 Saudi Arabia
      • 9.6.3.1 Key Country Dynamics
      • 9.6.3.2 Saudi Arabia Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
      • 9.6.3.3 Target Disease Prevalence
      • 9.6.3.4 Competitive Scenario
      • 9.6.3.5 Regulatory Framework
      • 9.6.3.6 Reimbursement Scenario
    • 9.6.4 UAE
      • 9.6.4.1 Key Country Dynamics
      • 9.6.4.2 UAE Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
      • 9.6.4.3 Target Disease Prevalence
      • 9.6.4.4 Competitive Scenario
      • 9.6.4.5 Regulatory Framework
      • 9.6.4.6 Reimbursement Scenario
    • 9.6.5 KUWAIT
      • 9.6.5.1 Key Country Dynamics
      • 9.6.5.2 Kuwait Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
      • 9.6.5.3 Target Disease Prevalence
      • 9.6.5.4 Competitive Scenario
      • 9.6.5.5 Regulatory Framework
      • 9.6.5.6 Reimbursement Scenario

Chapter 10 Competitive Landscape

  • 10.1 Company Categorization
  • 10.2 Participant's Overview
  • 10.3 Financial Performance
  • 10.4 Product Benchmarking
  • 10.5 Company Market Positioning
  • 10.6 Company Market Share Analysis, 2022
  • 10.7 Company Heat Map Analysis
  • 10.8 Strategic Initiatives
  • 10.9 Company Profiles
    • 10.9.1 NOVO NORDISK A/S
    • 10.9.2 TAKEDA PHARMACEUTICAL COMPANY LIMITED
    • 10.9.3 F. HOFFMANN LA-ROCHE LTD.
    • 10.9.4 BAYER AG
    • 10.9.5 PFIZER, INC.
    • 10.9.6 CSL BEHRING
    • 10.9.7 BIOMARIN
    • 10.9.8 OCTOPHARMA AG
    • 10.9.9 SANOFI
    • 10.9.10 SPARK THERAPEUTICS, INC.

List of Tables

  • TABLE 1 List of Abbreviation
  • TABLE 2 Global Hemophilia Market, By Region, 2018 - 2030 (USD Million)
  • TABLE 3 North America Hemophilia Market, By Country, 2018 - 2030 (USD Million)
  • TABLE 4 North America Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 5 North America Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 6 North America Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 7 North America Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 8 U.S. Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 9 U.S. Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 10 U.S. Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 11 U.S. Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 12 Canada Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 13 Canada Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 14 Canada Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 15 Canada Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 16 Europe Hemophilia Market, By Country, 2018 - 2030 (USD Million)
  • TABLE 17 Europe Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 18 Europe Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 19 Europe Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 20 Europe Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 21 UK Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 22 UK Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 23 UK Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 24 UK Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 25 Germany Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 26 Germany Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 27 Germany Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 28 Germany Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 29 France Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 30 France Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 31 France Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 32 France Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 33 Italy Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 34 Italy Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 35 Italy Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 36 Italy Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 37 Spain Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 38 Spain Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 39 Spain Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 40 Spain Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 41 Denmark Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 42 Denmark Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 43 Denmark Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 44 Denmark Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 45 Sweden Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 46 Sweden Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 47 Sweden Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 48 Sweden Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 49 Norway Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 50 Norway Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 51 Norway Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 52 Norway Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 53 Asia Pacific Hemophilia Market, By Country, 2018 - 2030 (USD Million)
  • TABLE 54 Asia Pacific Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 55 Asia Pacific Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 56 Asia Pacific Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 57 Asia Pacific Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 58 Japan Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 59 Japan Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 60 Japan Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 61 Japan Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 62 China Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 63 China Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 64 China Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 65 China Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 66 India Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 67 India Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 68 India Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 69 India Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 70 South Korea Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 71 South Korea Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 72 South Korea Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 73 South Korea Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 74 Australia Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 75 Australia Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 76 Australia Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 77 Australia Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 78 Thailand Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 79 Thailand Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 80 Thailand Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 81 Thailand Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 82 Latin America Hemophilia Market, By Country, 2018 - 2030 (USD Million)
  • TABLE 83 Latin America Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 84 Latin America Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 85 Latin America Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 86 Latin America Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 87 Mexico Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 88 Mexico Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 89 Mexico Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 90 Mexico Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 91 Brazil Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 92 Brazil Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 93 Brazil Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 94 Brazil Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 95 Argentina Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 96 Argentina Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 97 Argentina Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 98 Argentina Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 99 MEA Hemophilia Market, By Country, 2018 - 2030 (USD Million)
  • TABLE 100 MEA Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 101 MEA Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 102 MEA Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 103 MEA Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 104 South Africa Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 105 South Africa Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 106 South Africa Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 107 South Africa Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 108 Saudi Arabia Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 109 Saudi Arabia Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 110 Saudi Arabia Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 111 Saudi Arabia Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 112 UAE Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 113 UAE Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 114 UAE Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 115 UAE Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 116 KUWAIT Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 117 KUWAIT Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 118 KUWAIT Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 119 KUWAIT Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information procurement
  • FIG. 3 Market summary
  • FIG. 4 Market segmentation & scope
  • FIG. 5 Market size and growth prospects
  • FIG. 6 Global hemophilia market- Key market driver analysis
  • FIG. 7 Global hemophilia market - Key market restraint analysis
  • FIG. 8 Penetration & growth prospect mapping
  • FIG. 9 Global hemophilia market - Porter's analysis
  • FIG. 10 Global hemophilia market - PESTEL analysis
  • FIG. 11 Global hemophilia market type outlook key takeaways
  • FIG. 12 Global hemophilia market: Type movement analysis
  • FIG. 13 Hemophilia A market estimates, 2018 - 2030 (USD Million)
  • FIG. 14 Hemophilia B market estimates, 2018 - 2030 (USD Million)
  • FIG. 15 Others market estimates, 2018 - 2030 (USD Million)
  • FIG. 16 Global hemophilia market treatment outlook key takeaways
  • FIG. 17 Global hemophilia market: Treatment Type movement analysis
  • FIG. 18 On-demand market estimates, 2018 - 2030 (USD Million)
  • FIG. 19 Cure market estimates, 2018 - 2030 (USD Million)
  • FIG. 20 Prophylaxis market estimates, 2018 - 2030 (USD Million)
  • FIG. 21 Global hemophilia market therapy outlook key takeaways
  • FIG. 22 Global hemophilia market: Therapy movement analysis
  • FIG. 23 Factor Replacement Therapy market estimates, 2018 - 2030 (USD Million)
  • FIG. 24 Desmopressin & Fibrin Sealants market estimates, 2018 - 2030 (USD Million)
  • FIG. 25 Gene Therapy & Monoclonal Antibodies market estimates, 2018 - 2030 (USD Million)
  • FIG. 26 Regional marketplace: Key takeaways
  • FIG. 27 Global hemophilia market: Regional movement analysis
  • FIG. 28 North America hemophilia market, 2018 - 2030 (USD Million)
  • FIG. 29 U.S. hemophilia market, 2018 - 2030 (USD Million)
  • FIG. 30 Canada hemophilia market, 2018 - 2030 (USD Million)
  • FIG. 31 Europe hemophilia market, 2018 - 2030 (USD Million)
  • FIG. 32 UK hemophilia market, 2018 - 2030 (USD Million)
  • FIG. 33 Germany hemophilia market, 2018 - 2030 (USD Million)
  • FIG. 34 France hemophilia market, 2018 - 2030 (USD Million)
  • FIG. 35 Spain hemophilia market, 2018 - 2030 (USD Million)
  • FIG. 36 Italy hemophilia market, 2018 - 2030 (USD Million)
  • FIG. 37 Denmark hemophilia market, 2018 - 2030 (USD Million)
  • FIG. 38 Sweden hemophilia market, 2018 - 2030 (USD Million)
  • FIG. 39 Norway hemophilia market, 2018 - 2030 (USD Million)
  • FIG. 40 Asia Pacific hemophilia market, 2018 - 2030 (USD Million)
  • FIG. 41 Japan hemophilia market, 2018 - 2030 (USD Million)
  • FIG. 42 China hemophilia market, 2018 - 2030 (USD Million)
  • FIG. 43 India hemophilia market, 2018 - 2030 (USD Million)
  • FIG. 44 South Korea hemophilia market, 2018 - 2030 (USD Million)
  • FIG. 45 Australia hemophilia market, 2018 - 2030 (USD Million)
  • FIG. 46 Thailand hemophilia market, 2018 - 2030 (USD Million)
  • FIG. 47 Latin America hemophilia market, 2018 - 2030 (USD Million)
  • FIG. 48 Brazil hemophilia market, 2018 - 2030 (USD Million)
  • FIG. 49 Mexico hemophilia market, 2018 - 2030 (USD Million)
  • FIG. 50 Argentina hemophilia market, 2018 - 2030 (USD Million)
  • FIG. 51 MEA hemophilia market, 2018 - 2030 (USD Million)
  • FIG. 52 South Africa hemophilia market, 2018 - 2030 (USD Million)
  • FIG. 53 Saudi Arabia hemophilia market, 2018 - 2030 (USD Million)
  • FIG. 54 UAE market, 2018 - 2030 (USD Million)
  • FIG. 55 Kuwait market, 2018 - 2030 (USD Million)
  • FIG. 56 Strategy framework